Clinical trial
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in…
NCT00440973 · The Methodist Hospital Research Institute, Other · Terminated
Key facts
| NCT number | NCT00440973 |
|---|---|
| Title | Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer |
| Official title | Phase II Study of Interleukin- 2 and Bevacizumab in Patients With Progressive Metastatic Renal Cell Carcinoma |
| Lead sponsor | The Methodist Hospital Research Institute, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Bevacizumab, Interleukin-2 |
| Enrollment | 6 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Feb 27, 2007 |
| Last update posted | Mar 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: